Preparation and Characterization of an Oral Vaccine Formulation Using Electrosprayed Chitosan Microparticles
Chitosan particles loaded with the antigen ovalbumin (OVA) and the adjuvant Quil-A were produced by electrospray, using mixtures of water/ethanol/acetic acid as a solvent. Three different chitosans designed as HMC+70, HMC+85, and HMC+90 (called as 705010, 855010, and 905010) were tested and its efficacy to be used in oral vaccine delivery applications was investigated. The morphology, size, and zeta potential of the produced particles were investigated, together with the encapsulation efficiency and release of OVA from the three chitosan formulations. Moreover, the mucoadhesion and cytotoxicity of the chitosan microparticles was examined. All the three formulations with OVA and Quil-A were in the micrometer size range and had a positive zeta potential between 46 and 75 mV. Furthermore, all the three formulations displayed encapsulation efficiencies above 80% and the release of OVA over a period of 80 h was observed to be between 38 and 47%. None of the developed formulations exhibited high mucoadhesive properties, either cytotoxicity. The formulation prepared with HMC+70, OVA, and Quil-A had the highest stability within 2 h in buffer solution, as measured by dynamic light scattering. The electrosprayed formulation consisting of HMC+70 with OVA and Quil-A showed to be the most promising as an oral vaccine system.
KEY WORDSelectrohydrodynamics polysaccharide particles ovalbumin Quil-A
This study received support from The Danish National Research Foundation (Project DNRF122) and Villum Foundation’s Center (Grant No. 9301) for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN). Line Hagner Nielsen received financial support from the Danish Research Council for Technology and Production (FTP), Project DFF-4004-00120B. Furthermore, this study received financial support from the European Union’s Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 613931. Furthermore, Jorge Alberto S. Moreno received financial support from the Consejo Nacional de Ciencia y Tecnología (CONACYT) and the Instituto de Innovación y Transferencia de Tecnología (I2T2).
- 2.Gebril A, Alsaadi M, Acevedo R, Mullen AB, Ferro VA. Optimizing efficacy of mucosal vaccines. Expert Rev Vaccines. 2012;11(9):1139–55 Available from: http://informahealthcare.com/doi/abs/10.1586/erv.12.81%5Cn. http://www.ncbi.nlm.nih.gov/pubmed/23151169.CrossRefGoogle Scholar
- 4.Rizwan SB, McBurney WT, Young K, Hanley T, Boyd BJ, Rades T, et al. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. J Control Release. 2013;165(1):16–21. Available from:. https://doi.org/10.1016/j.jconrel.2012.10.020.CrossRefPubMedGoogle Scholar
- 6.Fujkuyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, et al. Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines. 2012;11(3):367–79 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3315788&tool=pmcentrez&rendertype=abstract.CrossRefGoogle Scholar
- 18.Gallovic MD, Schully KL, Bell MG, Elberson MA, Palmer JR, Darko CA, et al. Acetalated dextran microparticulate vaccine formulated via coaxial electrospray preserves toxin neutralization and enhances murine survival following inhalational bacillus anthracis exposure. Adv Healthc Mater. 2016;5(20):2617–27.CrossRefGoogle Scholar
- 21.Junkins RD, Gallovic MD, Johnson BM, Collier MA, Watkins-Schulz R, Cheng N, et al. A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. J Control Release. 2018;270:1–13 Available from: http://linkinghub.elsevier.com/retrieve/pii/S016836591731026X.CrossRefGoogle Scholar
- 23.Suksamran T, Ngawhirunpat T, Rojanarata T, Sajomsang W, Pitaksuteepong T, Opanasopit P. Methylated N-(4-N,N-dimethylaminocinnamyl) chitosan-coated electrospray OVA-loaded microparticles for oral vaccination. Int J Pharm. 2013;448(1):19–27. Available from:. https://doi.org/10.1016/j.ijpharm.2013.03.015.CrossRefPubMedGoogle Scholar
- 30.von Halling Laier C, Gibson B, van de Weert M, Boyd BJ, Rades T, Boisen A, et al. Spray dried cubosomes with ovalbumin and Quil-A as a nanoparticulate dry powder vaccine formulation. Int J Pharm. 2018;550:35–44 Available from: https://www.sciencedirect.com/science/article/pii/S0378517318306148?via%3Dihub.CrossRefGoogle Scholar
- 33.Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems -a review (part 2). Trop J Pharm Res April J Cit ReportsScience Ed [Internet]. 2013 [cited 2016 Jun 24];12(122):265–265. Available from: http://www.tjpr.org
- 34.Jiang L, Duan H, Ji X, Wang T, Wang Y, Qiu J. Application of a simple desolvation method to increase the formation yield, physical stability and hydrophobic drug encapsulation capacity of chitosan-based nanoparticles. Int J Pharm. 2018;545(1–2):117–27 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0378517318301893.CrossRefGoogle Scholar
- 37.Mowat AM, Donachie AM, Reid G, Jarrett O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology. 1991;72(3):317–22 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1384389&tool=pmcentrez&rendertype=abstract.PubMedPubMedCentralGoogle Scholar
- 39.Fukui Y, Maruyama T, Iwamatsu Y, Fujii A, Tanaka T, Ohmukai Y, et al. Preparation of monodispersed polyelectrolyte microcapsules with high encapsulation efficiency by an electrospray technique. Colloids Surf A Physicochem Eng Asp. 2010;370(1–3):28–34. Available from:. https://doi.org/10.1016/j.colsurfa.2010.08.039.CrossRefGoogle Scholar
- 40.Nath SD, Son S, Sadiasa A, Min YK, Lee BT. Preparation and characterization of PLGA microspheres by the electrospraying method for delivering simvastatin for bone regeneration. Int J Pharm. 2013;443(1–2):87–94. Available from:. https://doi.org/10.1016/j.ijpharm.2012.12.037.CrossRefPubMedGoogle Scholar
- 44.Kaneko K, McDowell A, Ishii Y, Hook S. Characterization and evaluation of stabilized particulate formulations as therapeutic oral vaccines for allergy. J Liposome Res [Internet]. 2017;1–9. Available from: https://www.tandfonline.com/doi/full/10.1080/08982104.2017.1370472.